UK Markets open in 6 hrs 57 mins

Sanofi (0O59.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
78.79+1.18 (+1.51%)
At close: 06:08PM BST
Full screen
Previous close77.61
Open77.56
Bid77.99 x 0
Ask79.79 x 0
Day's range77.42 - 79.33
52-week range2.39 - 106.64
Volume1,463,026
Avg. volume1,727,063
Market cap99.866B
Beta (5Y monthly)0.36
PE ratio (TTM)16.08
EPS (TTM)4.90
Earnings dateN/A
Forward dividend & yield3.33 (3.42%)
Ex-dividend date06 May 2022
1y target estN/A
  • Globe Newswire

    Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

    Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trialsAbout 75,000 adults in the U.S. living with prurigo nodularis are most in need of new treatment options Approval represents the second dermatology indication for Dupixent and fifth disease indication overall in the U.S. Paris and Tarrytown, N.Y. September 28, 2022

  • Reuters

    French drugmaker Sanofi expects positive boost from currency markets in Q3

    PARIS (Reuters) -French drugmaker Sanofi said it expected a positive boost to its third-quarter business results from movements on the currency markets, helped by the strength of the U.S. dollar since Sanofi does much of its business in the United States. Sanofi said its preliminary estimate of currency impacts on its third-quarter 2022 sales was for a boost of approximately 10% to 11%, and for a lift of around 12% and 13% on its business earnings per share (EPS). Sanofi will report third-quarter results on Oct. 28.

  • Globe Newswire

    Press Release: Availability of the Q3 2022 Memorandum for modelling purposes

    Availability of the Q3 2022 Memorandum for modelling purposes Paris, France – September 28, 2022 - Sanofi announced today that its Q3 2022 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q3-results-2022 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on variou